Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesComparison of laparoscopic inversion esophagectomy and open transhiatal esophagectomy for high-grade dysplasia and stage I esophageal adenocarcinoma
Archives of Surgery, 07/24/09
Perry KA et al. - In a study to assess whether perioperative outcomes of laparoscopic inversion esophagectomy (LIE) are comparable to those of open transhiatal esophagectomy (THE), it appears that LIE is a safe and effective approach to treatment of high-grade dysplasia and early esophageal adenocarcinoma. Compared with THE, LIE decreases operative blood loss and length of hospital stay without increasing the operative time, morbidity, or mortality related to esophagectomy.
Methods- 21 consecutive pts underwent LIE for high-grade dysplasia or clinical stage I esophageal cancer.
- Pts were compared with 21 stage-matched control pts treated with THE.
- Main outcomes were operative time, blood loss, length of hospital stay, perioperative complications, and disease-free survival.
- Mean operative times for LIE (399 mins) and THE (407 mins) were not significantly different.
- Pts undergoing LIE had significantly lower intraoperative blood loss (168 mL) and overall length of hospital stay (10 days) compared with those in the THE group (526 mL and 14 days, respectively).
- Complication rates were not significantly different between the groups.
- With a median follow-up of 29 mos, there has been 1 systemic recurrence in the LIE group.
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: The FOCUS Trial
Journal of Clinical Oncology, 10/30/09
Sponsor
Article Search
Sponsor
Sponsor